2023 № 3 Issues of payments for medicines in the provision of specialized medical care for compulsory medical insurance
In the article, on the basis of regulatory legal acts, the issues of the legality of the use of co-financing mechanisms (co-payments) in the system of compulsory medical insurance are considered.
The situations and conditions in which co-payments are legitimate are analyzed.
It is concluded that it is necessary not to combat this phenomenon, but to regulate cases of co-payments on the part of insured citizens.
2023 № 2 Analysis of drug supply for patients with malignant neoplasms at the inpatient stage of treatment.
Drug provision of patients with malignant neoplasms in a hospital and day hospital in the constituent entities and Federal districts of the Russian Federation has not been studied enough. Meanwhile, hundreds of billions of rubles are annually spent on the purchase of drugs for these patients. The aim of the study is to analyze the drug supply of patients with malignant neoplasms at the inpatient stage of treatment. We analyzed the purchase of medicines at the expense of compulsory medical insurance in the subjects and federal districts of the Russian Federation according to the website zakupki.gov.ru. To compare federal districts and constituent entities with each other, we compared the amounts spent on the purchase of medicines at the expense of compulsory medical insurance, in terms of 1 patient with a newly diagnosed cancer in each federal district and constituent entity, respectively. We found significant differences
in the drug treatment of patients with MN not only between the Federal Districts, but also within the Federal District. Moreover, the difference in drug provision of patients with specific drugs in the subjects reaches multiple values. Oral drugs are also used differently, with a mixed trend in the Federal Districts of their use over the past two years. Drug provision of patients with malignant neoplasms in the constituent entities of the Russian Federation at the inpatient stage of treatment varies significantly, patients have different access to drugs with oral administration.